# Michael A. Carducci

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-a-carducci/

## Facts

| Field | Value |
| --- | --- |
| Citations | 55,554 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 104 |
| i10-index | 402 |
| Last Known Institution | Johns Hopkins University |
| OpenAlex ID | https://openalex.org/A5001783218 |
| ORCID iD | 0000-0002-7908-1215 |
| Works | 1,049 |

## Researcher papers

Showing 12 of 13.

- [Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/temsirolimus-interferon-alfa-or-both-for-advanced-renal-cell-carcinoma/)
- [Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer](https://scholariq.org/papers/chemohormonal-therapy-in-metastatic-hormone-sensitive-prostate-cancer/)
- [AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer](https://scholariq.org/papers/ar-v7-and-resistance-to-enzalutamide-and-abiraterone-in-prostate-cancer/)
- [Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group](https://scholariq.org/papers/design-and-end-points-of-clinical-trials-for-patients-with-progressive-prostate/)
- [Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial](https://scholariq.org/papers/psilocybin-produces-substantial-and-sustained-decreases-in-depression-and/)
- [Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study](https://scholariq.org/papers/denosumab-versus-zoledronic-acid-for-treatment-of-bone-metastases-in-men-with/)
- [Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3](https://scholariq.org/papers/trial-design-and-objectives-for-castration-resistant-prostate-cancer-updated/)
- [Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer](https://scholariq.org/papers/outcomes-of-observation-vs-stereotactic-ablative-radiation-for-oligometastatic/)
- [Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial](https://scholariq.org/papers/chemohormonal-therapy-in-metastatic-hormone-sensitive-prostate-cancer-long-term/)
- [Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group](https://scholariq.org/papers/eligibility-and-response-guidelines-for-phase-ii-clinical-trials-in-androgen/)
- [Kidney Cancer](https://scholariq.org/papers/kidney-cancer/)
- [Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/circulating-tumor-cell-counts-are-prognostic-of-overall-survival-in-swog-s0421-a/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Vitamin C and Antioxidants Research](https://scholariq.org/topics/vitamin-c-and-antioxidants-research/)

## Researcher university

- [Johns Hopkins University](https://scholariq.org/institutions/johns-hopkins-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.